标题
Getting TRAIL back on track for cancer therapy
作者
关键词
-
出版物
CELL DEATH AND DIFFERENTIATION
Volume 21, Issue 9, Pages 1350-1364
出版商
Springer Nature
发表日期
2014-06-20
DOI
10.1038/cdd.2014.81
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Systemic use of tumor necrosis factor alpha as an anticancer agent
- (2015) Nicholas J. Roberts et al. Oncotarget
- TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells
- (2014) Susann Voigt et al. BMC CANCER
- Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
- (2014) Joachim von Pawel et al. Clinical Lung Cancer
- Immunoglobulin Fc Domain Fusion to TRAIL Significantly Prolongs Its Plasma Half-Life and Enhances Its Antitumor Activity
- (2014) H. Wang et al. MOLECULAR CANCER THERAPEUTICS
- Necroptosis
- (2014) Andreas Linkermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer†
- (2013) A. L. Cohn et al. ANNALS OF ONCOLOGY
- TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer
- (2013) Charles S. Fuchs et al. CANCER
- Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells
- (2013) E Passante et al. CELL DEATH AND DIFFERENTIATION
- Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
- (2013) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family
- (2013) K Azijli et al. CELL DEATH AND DIFFERENTIATION
- Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis
- (2013) D Westphal et al. CELL DEATH AND DIFFERENTIATION
- Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death
- (2013) Xin Chen et al. CELL RESEARCH
- Molecular Pathways: Targeting Inhibitor of Apoptosis Proteins in Cancer--From Molecular Mechanism to Therapeutic Application
- (2013) S. Fulda CLINICAL CANCER RESEARCH
- A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
- (2013) Zev A. Wainberg et al. Clinical Colorectal Cancer
- Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response
- (2013) Michel DuPage et al. CURRENT OPINION IN IMMUNOLOGY
- Death receptor agonist therapies for cancer, which is the right TRAIL?
- (2013) Pamela M. Holland CYTOKINE & GROWTH FACTOR REVIEWS
- Nuclear Death Receptor TRAIL-R2 Inhibits Maturation of Let-7 and Promotes Proliferation of Pancreatic and Other Tumor Cells
- (2013) Verena Haselmann et al. GASTROENTEROLOGY
- The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism
- (2013) James M. Murphy et al. IMMUNITY
- Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors
- (2013) Sunil Sharma et al. INVESTIGATIONAL NEW DRUGS
- A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2013) Luis Paz-Ares et al. Journal of Thoracic Oncology
- A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer
- (2013) Martin Reck et al. LUNG CANCER
- APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fc Receptors
- (2013) C. Gieffers et al. MOLECULAR CANCER THERAPEUTICS
- Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis
- (2013) Zhenyu Cai et al. NATURE CELL BIOLOGY
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Mechanisms of Action of Bcl-2 Family Proteins
- (2013) A. Shamas-Din et al. Cold Spring Harbor Perspectives in Biology
- Inhibitor of Apoptosis (IAP) Proteins-Modulators of Cell Death and Inflammation
- (2013) J. Silke et al. Cold Spring Harbor Perspectives in Biology
- Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer
- (2013) Andres Forero-Torres et al. Cancer Medicine
- A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
- (2012) H. L. Kindler et al. ANNALS OF ONCOLOGY
- Proapoptotic Activation of Death Receptor 5 on Tumor Endothelial Cells Disrupts the Vasculature and Reduces Tumor Growth
- (2012) Nicholas S. Wilson et al. CANCER CELL
- Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer
- (2012) Caio M. Rocha Lima et al. CANCER INVESTIGATION
- Abstract 3853: TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches
- (2012) Heather Huet et al. CANCER RESEARCH
- Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase
- (2012) Liming Sun et al. CELL
- TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation
- (2012) S Jouan-Lanhouet et al. CELL DEATH AND DIFFERENTIATION
- Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells?
- (2012) L.H.A.M. de Wilt et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study
- (2012) George D. Demetri et al. EUROPEAN JOURNAL OF CANCER
- Cellular FLICE-like inhibitory proteins (c-FLIPs): Fine-tuners of life and death decisions
- (2012) Selcen Öztürk et al. EXPERIMENTAL CELL RESEARCH
- Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients
- (2012) Jochen Tuettenberg et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors
- (2012) Melinda S. Merchant et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist
- (2012) V. Subbiah et al. MOLECULAR CANCER THERAPEUTICS
- A Death Effector Domain Chain DISC Model Reveals a Crucial Role for Caspase-8 Chain Assembly in Mediating Apoptotic Cell Death
- (2012) Laura S. Dickens et al. MOLECULAR CELL
- Stoichiometry of the CD95 Death-Inducing Signaling Complex: Experimental and Modeling Evidence for a Death Effector Domain Chain Model
- (2012) Kolja Schleich et al. MOLECULAR CELL
- TRAF2 Sets a Threshold for Extrinsic Apoptosis by Tagging Caspase-8 with a Ubiquitin Shutoff Timer
- (2012) Francois Gonzalvez et al. MOLECULAR CELL
- Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
- (2012) David L. Lacey et al. NATURE REVIEWS DRUG DISCOVERY
- ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells
- (2012) S Cristofanon et al. Cell Death & Disease
- Recent advances in apoptosis, mitochondria and drug resistance in cancer cells
- (2011) Inthrani R. Indran et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
- Caspase-8 and Bid: Caught in the act between death receptors and mitochondria
- (2011) Chahrazade Kantari et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein
- (2011) Guan Wang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
- (2011) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- cIAPs Block Ripoptosome Formation, a RIP1/Caspase-8 Containing Intracellular Cell Death Complex Differentially Regulated by cFLIP Isoforms
- (2011) Maria Feoktistova et al. MOLECULAR CELL
- Catalytic activity of the caspase-8–FLIPL complex inhibits RIPK3-dependent necrosis
- (2011) Andrew Oberst et al. NATURE
- TRAIL-R4 Promotes Tumor Growth and Resistance to Apoptosis in Cervical Carcinoma HeLa Cells through AKT
- (2011) Najoua Lalaoui et al. PLoS One
- Molecular biology of Bax and Bak activation and action
- (2010) Dana Westphal et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
- (2010) A Younes et al. BRITISH JOURNAL OF CANCER
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
- (2010) T Trarbach et al. BRITISH JOURNAL OF CANCER
- Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
- (2010) D Lecis et al. BRITISH JOURNAL OF CANCER
- Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)
- (2010) Andres Forero-Torres et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors
- (2010) T. Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane
- (2010) Z T Schug et al. CELL DEATH AND DIFFERENTIATION
- Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level
- (2010) A Morizot et al. CELL DEATH AND DIFFERENTIATION
- A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
- (2010) D. R. Camidge et al. CLINICAL CANCER RESEARCH
- A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
- (2010) R. S. Herbst et al. CLINICAL CANCER RESEARCH
- Oncogenic K-Ras Turns Death Receptors Into Metastasis-Promoting Receptors in Human and Mouse Colorectal Cancer Cells
- (2010) Frederik J.H. Hoogwater et al. GASTROENTEROLOGY
- Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
- (2010) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- CD11c+ Dendritic Cells and B Cells Contribute to the Tumoricidal Activity of Anti-DR5 Antibody Therapy in Established Tumors
- (2010) N. M. Haynes et al. JOURNAL OF IMMUNOLOGY
- TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5
- (2010) Johannes Lemke et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
- (2009) H. A. Wakelee et al. ANNALS OF ONCOLOGY
- Is TRAIL the holy grail of cancer therapy?
- (2009) Thomas Newsom-Davis et al. APOPTOSIS
- Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family
- (2009) Tobias Schilling et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Structural Basis for the Lack of E2 Interaction in the RING Domain of TRAF2
- (2009) Qian Yin et al. BIOCHEMISTRY
- Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling
- (2009) Zhaoyu Jin et al. CELL
- Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
- (2009) C. H. Mom et al. CLINICAL CANCER RESEARCH
- TRAF2 Must Bind to Cellular Inhibitors of Apoptosis for Tumor Necrosis Factor (TNF) to Efficiently Activate NF-κB and to Prevent TNF-induced Apoptosis
- (2009) James E. Vince et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The E3 Ubiquitin Ligase cIAP1 Binds and Ubiquitinates Caspase-3 and -7 via Unique Mechanisms at Distinct Steps in Their Processing
- (2009) Young Eun Choi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment
- (2009) Peter Geserick et al. JOURNAL OF CELL BIOLOGY
- Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
- (2009) Stephen Leong et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer: It Does Not Always Fade With Time
- (2009) Jean-Yves Douillard JOURNAL OF CLINICAL ONCOLOGY
- Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer
- (2009) Tom M. Ganten et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- XIAP discriminates between type I and type II FAS-induced apoptosis
- (2009) Philipp J. Jost et al. NATURE
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
- (2009) M. Olivier et al. Cold Spring Harbor Perspectives in Biology
- Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance
- (2008) M. Fakler et al. BLOOD
- BH3 Mimetic ABT-737 Potentiates TRAIL-Mediated Apoptotic Signaling by Unsequestering Bim and Bak in Human Pancreatic Cancer Cells
- (2008) S. Huang et al. CANCER RESEARCH
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4
- (2008) M Todaro et al. CELL DEATH AND DIFFERENTIATION
- A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies
- (2008) S. J. Hotte et al. CLINICAL CANCER RESEARCH
- Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
- (2008) F. Anthony Greco et al. LUNG CANCER
- Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology
- (2008) S WANG et al. TRENDS IN PHARMACOLOGICAL SCIENCES
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started